Novo Nordisk’s CagriSema bested by Lilly’s Zepbound in head-to-head trial

Novo Nordisk’s CagriSema has been outperformed by Eli Lilly’s Zepbound (tirzepatide) in a head-to-head obesity trial. The ...
The Manila Times

Novo Nordisk A/S: CagriSema demonstrated 23% weight loss in an open-label head-to-head REDEFINE 4 trial in people with obesity, the primary endpoint was not achie…

CagriSema achieved 23% weight loss after 84 weeks of treatmentCagriSema 2.4/2.4 mg did not meet the primary endpoint of ...
Nasdaq

Satellos Announces Encouraging Functional Data from the 28-day Phase 1b Open-Label Trial of SAT-3247 in Adults with Duchenne Muscular Dystrophy

Phase 1b data shows treatment with SAT-3247 was safe and well-tolerated Pharmacokinetic (PK) profile of SAT-3247 translated as expected to Duchenne Muscular Dystrophy (DMD) patients taking concurrent ...
ascopubs.org

First-Line Lenvatinib Plus Pembrolizumab Versus Chemotherapy for Advanced Endometrial Cancer: A Randomized, Open-Label, Phase III Trial

Abemaciclib Plus Fulvestrant in Advanced Breast Cancer After Progression on CDK4/6 Inhibition: Results From the Phase III postMONARCH Trial Patients with stage III to IV or recurrent, radiographically ...
ascopubs.org

Methotrexate, Doxorubicin, and Cisplatin Versus Methotrexate, Doxorubicin, and Cisplatin + Ifosfamide in Poor Responders to Preoperative Chemotherapy for Newly Diagnosed High ...

Endocrine Therapy Omission in Estrogen Receptor–Low (1%-10%) Early-Stage Breast Cancer JCOG0905 is a multicenter, open-label, multi-institutional, randomized trial ...

Novo Nordisk’s stock closes at 4-year low after its next-gen weight-loss drug lost to Lilly’s in Phase 3 trial

Novo Nordisk shares were under pressure on Monday as the struggling Danish pharmaceutical said a head-to-head study found a drug in development didn’t cut as much weight as an Eli Lilly product.
Seeking Alpha

Edgewise Therapeutics: Strong Open Label Data Makes For A Bullish Signal

Edgewise Therapeutics develops small molecules for myopathies, with lead molecule sevasemten in phase 3 for Becker Muscular Dystrophy. Company was founded in 2017, backed by OrbiMed, with an ...